Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03193528Active Not Recruiting

A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer

Role: collaborator

NCT03193541Recruiting

A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

Role: collaborator

NCT04564781Recruiting

Predicting BCG Response

Role: collaborator

NCT03193515Recruiting

A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer

Role: collaborator

NCT05347342Active Not Recruiting

A Diagnostic for the Early Detection of Bladder Cancer

Role: collaborator

All 5 trials loaded